{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:21:11Z","timestamp":1793575271412,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lilit Ghazaryan and Aditi Mehta, both of Costello Medical, London, UK"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the 2-year impact of bimekizumab on health status, work productivity and indirect cost savings in patients with active PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>BE OPTIMAL [NCT03895203; biologic disease-modifying anti-rheumatic drug (bDMARD)-na\u00efve] and BE COMPLETE [NCT03896581; tumor necrosis factor inhibitor inadequate response\/intolerance (TNFi-IR)] assessed subcutaneous bimekizumab 160\u2009mg every 4\u2009weeks. BE OPTIMAL week 52\/BE COMPLETE week 16 completers could enter BE VITAL (NCT04009499; open-label extension), where all patients received bimekizumab. Outcomes reported for placebo- and bimekizumab-randomized patients to year 2 were changes in health status (EQ-5D-3L) and work productivity [Work Productivity and Activity Impairment Questionnaire\u2014Specific Health Problem v2.0 (WPAI-SHP)], associations between disease control criteria and WPAI-SHP, and annualized indirect cost savings (estimated by multiplying 2022 average wages by improvements in overall work impairment). Missing data were imputed using multiple (continuous) or non-responder (binary) imputation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 712 bDMARD-na\u00efve and 400 TNFi-IR patients, improvements from baseline in mean EQ-5D-3L visual analog scale scores were sustained to year 2, with scores improving by 24.6\u201338.9%. A minimal clinically important difference in overall work impairment was achieved by 51.1\u201364.8% of patients at year 1, and this was largely sustained to year 2 (44.3\u201351.6%). The greatest work productivity improvements were observed in patients who achieved stringent disease control across both musculoskeletal and skin domains. In Europe, indirect cost savings at year 1 (US$7965\u201311\u2009517) were sustained to year 2 (US$7789\u201312\u2009018); trends were similar in the USA and Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bimekizumab treatment resulted in sustained improvements in health status and work productivity to year 2, with substantial potential for long-term indirect cost savings, regardless of prior TNFi experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkag009","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:53:50Z","timestamp":1769086430000},"source":"Crossref","is-referenced-by-count":1,"title":["Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"first","affiliation":[{"name":"Royal National Hospital of Rheumatic Diseases , Bath,","place":["UK"]},{"name":"Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath , Bath,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2018Epid\u00e9miologie et de Sant\u00e9 Publique , Paris,","place":["France"]},{"name":"Rheumatology Department, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-4205","authenticated-orcid":false,"given":"M Elaine","family":"Husni","sequence":"additional","affiliation":[{"name":"Department of Rheumatic and Immunologic Diseases, Cleveland Clinic , Cleveland, OH,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences , Nagoya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ink","sequence":"additional","affiliation":[{"name":"UCB , Slough,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7857-8783","authenticated-orcid":false,"given":"Rajan","family":"Bajracharya","sequence":"additional","affiliation":[{"name":"UCB , Slough,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Healy","sequence":"additional","affiliation":[{"name":"UCB , Morrisville, NC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1987-1223","authenticated-orcid":false,"given":"Michael F","family":"M\u00f8rup","sequence":"additional","affiliation":[{"name":"UCB , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-0845","authenticated-orcid":false,"given":"Jessica A","family":"Walsh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health , Salt Lake City, UT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"2026021706512619800_rkag009-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021706512619800_rkag009-B2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2026021706512619800_rkag009-B3","doi-asserted-by":"crossref","first-page":"e001321","DOI":"10.1136\/rmdopen-2020-001321","article-title":"Patient\u2019s experience of psoriatic arthritis: a conceptual model based on qualitative interviews","volume":"6","author":"Ogdie","year":"2020","journal-title":"RMD Open"},{"key":"2026021706512619800_rkag009-B4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-022-00443-y","article-title":"Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence","volume":"9","author":"Coates","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2026021706512619800_rkag009-B5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"2026021706512619800_rkag009-B6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2026021706512619800_rkag009-B7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13075-024-03282-0","article-title":"Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis","volume":"26","author":"Gossec","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026021706512619800_rkag009-B8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s10926-013-9436-y","article-title":"What work means to people with work disability: a scoping review","volume":"24","author":"Saunders","year":"2014","journal-title":"J Occup Rehabil"},{"key":"2026021706512619800_rkag009-B9","doi-asserted-by":"crossref","first-page":"103987","DOI":"10.1016\/j.jvb.2024.103987","article-title":"Working with a chronic health condition: the implications of proactive vitality management for occupational health and performance","volume":"150","author":"den Kamp","year":"2024","journal-title":"J Vocat Behav"},{"key":"2026021706512619800_rkag009-B10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40273-018-0618-5","article-title":"Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review","volume":"36","author":"D\u2019Angiolella","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2026021706512619800_rkag009-B11","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee","year":"2010","journal-title":"Pharm Ther"},{"key":"2026021706512619800_rkag009-B12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00296-009-0936-1","article-title":"Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment","volume":"30","author":"Brodszky","year":"2009","journal-title":"Rheumatol Int"},{"key":"2026021706512619800_rkag009-B13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","article-title":"The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review","volume":"107","author":"Burgos-Pol","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"2026021706512619800_rkag009-B14","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/ard.2005.046367","article-title":"Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany","volume":"65","author":"Huscher","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2026021706512619800_rkag009-B15","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","article-title":"Societal costs and patients\u2019 experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study","volume":"76","author":"Kristensen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021706512619800_rkag009-B16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/14737167.2015.965154","article-title":"The indirect costs of psoriatic arthritis: systematic review and meta-analysis","volume":"15","author":"Kawalec","year":"2015","journal-title":"ExpertRev Pharmacoecon Outcomes Res"},{"key":"2026021706512619800_rkag009-B17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"2026021706512619800_rkag009-B18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"2026021706512619800_rkag009-B19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1744666X.2023.2277266","article-title":"Bimekizumab for the treatment of psoriatic arthritis","volume":"20","author":"Tanaka","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"2026021706512619800_rkag009-B20","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40744-024-00708-8","article-title":"Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026021706512619800_rkag009-B21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3899\/jrheum.2024-0923","article-title":"Bimekizumab improves patient-reported outcomes and work productivity in patients with psoriatic arthritis: 1-year results from two phase 3 studies","volume":"52","author":"Gladman","year":"2025","journal-title":"J Rheumatol"},{"key":"2026021706512619800_rkag009-B22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"2026021706512619800_rkag009-B23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"2026021706512619800_rkag009-B24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"2026021706512619800_rkag009-B25","author":"EuroQol Research Foundation","year":"2018"},{"key":"2026021706512619800_rkag009-B26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40744-019-0155-5","article-title":"A threshold of meaning for work disability improvement in psoriatic arthritis measured by the work productivity and activity impairment questionnaire","volume":"6","author":"Tillett","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2026021706512619800_rkag009-B27","article-title":"Average wages (indicator)","author":"Organization for Economic Co-operation and Development","year":"2020"},{"key":"2026021706512619800_rkag009-B28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40744-024-00642-9","article-title":"Work productivity and general health through 2 years of guselkumab treatment in a phase 3 randomized trial of patients with active psoriatic arthritis","volume":"11","author":"Curtis","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026021706512619800_rkag009-B29","article-title":"Comparable estimates of average wages per full-time equivalent employee","author":"Organization for Economic Co-operation and Development","year":"2023"},{"key":"2026021706512619800_rkag009-B30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/annrheumdis-2013-204948","article-title":"Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology","volume":"74","author":"Buch","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026021706512619800_rkag009-B31","doi-asserted-by":"crossref","first-page":"e003855","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"key":"2026021706512619800_rkag009-B32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/ard-2023-224431","article-title":"Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study","volume":"82","author":"Ritchlin","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026021706512619800_rkag009-B33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026021706512619800_rkag009-B34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/ced.15237","article-title":"Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12\/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review","volume":"47","author":"Xie","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2026021706512619800_rkag009-B35","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-78665-0","volume-title":"Handbook of disease burdens and quality of life measures","author":"Preedy","year":"2010"},{"key":"2026021706512619800_rkag009-B36","doi-asserted-by":"crossref","first-page":"1759720X221140846","DOI":"10.1177\/1759720X221140846","article-title":"Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis","volume":"14","author":"Tillett","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026021706512619800_rkag009-B37","doi-asserted-by":"crossref","first-page":"105534","DOI":"10.1016\/j.jbspin.2023.105534","article-title":"Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe","volume":"90","author":"Walsh","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2026021706512619800_rkag009-B38","first-page":"1227","article-title":"Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials","volume":"38","author":"Tillett","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2026021706512619800_rkag009-B39","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026021706512619800_rkag009-B40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3899\/jrheum.160180","article-title":"Mapping the effect of psoriatic arthritis using the international classification of functioning, disability and health","volume":"44","author":"Gudu","year":"2017","journal-title":"J Rheumatol"},{"key":"2026021706512619800_rkag009-B41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","article-title":"Work disability in psoriatic arthritis: a systematic review","volume":"51","author":"Tillett","year":"2012","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag009\/66569645\/rkag009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/1\/rkag009\/66569645\/rkag009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/1\/rkag009\/66569645\/rkag009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:51:39Z","timestamp":1771329099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag009\/8440776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag009","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag009"}}